Clinical trial Recruiting at 1 site Interventional Ages 18 to 50 Women only

Non-invasive vagus nerve stimulation for Temporomandibular Disorders (TMD) in premenopausal women

Official title: Pilot Study of the Effects of Transcutaneous Non-Invasive Vagus Nerve Stimulation (nVNS) on Symptoms and Brain Mechanisms in Premenopausal Women With Temporomandibular Disorders (TMD)

Run by University of California, Los Angeles · NCT07288411 · Data updated 2026-11-12

A non-invasive vagus nerve stimulation treatment is being tested to see if it helps with jaw pain and related symptoms in premenopausal women with TMD.

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment10 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Drugs / interventionsRadiation
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedDecember 2026
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedNovember 6, 2026
Trial IDNCT07288411 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Premenopausal women aged 18–50 with at least one cardinal TMD symptom (jaw pain, limited mouth opening, or TMJ noise) and no pregnancy.

Probably not a fit

Individuals who do not respond to nVNS or have factors that exclude participation (e.g., non-right-handed, language barriers, or medical conditions precluding participation) may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study tests a transcutaneous non-invasive vagus nerve stimulation (nVNS) approach in women aged 18–50 with temporomandibular disorders. Participants attend two in-clinic visits (baseline and after treatment) and receive nVNS twice weekly for eight weeks, with in-clinic assessments including physical exams, blood and saliva samples, and brain MRI. Home activities include stool sample collection and online questionnaires on mood, pain, and health behaviors. Data collected will help examine symptom changes and potential brain-level mechanisms related to the BGM axis in TMD.

Why it matters

Potential benefit: If successful, nVNS could reduce TMD pain and improve function for some patients.

How similar studies have gone: Prior studies in neuromodulation have shown potential in chronic pain, but results for TMD with this specific non-invasive approach remain exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ages 18-50
* Premenopausal menstruating women\*
* Participants report or present with at least 1 of 3 cardinal signs of TMD: jaw pain, limited mouth opening, or TMJ noise.
* Specific screening reveals clinical findings that include TMJ and/or masticatory and cervical muscle pain.
* Must have a negative urine test for pregnancy
* Ability to speak the English language fluently due to the standardized assessments involved
* Right-handed (participants are limited to right-handed individuals to reduce variability in brain lateralization and ensure more consistent, interpretable data).

  * Only premenopausal women are included to control for hormonal variability that may influence the results. Participants will be scheduled during their follicular phase based on self-reported last menstrual period to further reduce hormonal confounds.

Exclusion Criteria:

* Medical condition, laboratory finding, or physical exam finding that precludes participation, such as systemic arthritides, juvenile idiopathic arthritis, idiopathic condylar resorption, connective tissue disorders, mandibular osteonecrosis, mandibular and condylar fractures, salivary gland disorders (incl. history of stones or swelling), neoplasms, neurologic/neuropathic, endocrine, or immune/autoimmune diseases and congenital or developmental disorders.
* Pathologic processes found on imaging including neoplasm (Exception: disc displacements and osseous pathology including osteoarthritis/osteoarthrosis).
* Radiation treatment to head and neck
* Prior jaw or open TMJ (including contralateral joint) surgery including plication, chondroplasty, joint replacement, disectomy, and discoplasty.
* Intra-articular therapies of TMJ being sampled that include arthrocentesis, visco-supplementation, and steroid, platelet-rich plasma/platelet-rich fibrin administration within the last 6mo
* Recent febrile illness within the past 8 weeks that precludes or delays participation by more than 90 days
* Trauma to jaw in the last 2mo
* Presence of non-TMD orofacial pain disorders excluding comorbidity of interest (fibromyalgia).
* Pregnancy or lactation
* Undergoing or previously undergone bone anabolic or other hormonal therapies for medical needs
* Unable to participate due to language barrier or mental/intellectual incompetence
* Use of antidepressant drugs unless the participants have been on a stable dose for 60 days.
* Drug and/or alcohol abuse in the past year
* Ongoing dental treatments requiring invasive procedures (e.g. implant placement, tooth extractions, etc.)
* Recent dental treatments within past two weeks that required sustained mouth opening for more than 20 minutes.
* Wearing removable or implant supported dentures or fixed orthodontic appliances
* Unable or unwilling to give informed consent
* Participation in another clinical study that interferes with participation in this study
* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
* Presence of non-TMD orofacial pain disorders such as that from periodontal disease and carious lesions.
* Presence of major psychiatric diagnosis such as schizophrenia, bipolar disorder, post-traumatic stress disorder, obsessive compulsive disorder, or current history of drug or alcohol abuse.
* Individuals with current regular use of narcotics and/or opioids. Use of centrally acting medications that will interfere with neuroimaging testing, such as systemic steroids, opiate analgesics.
* Smokes/Vapes tobacco more than 1/3 pack per day

Where it's running

  • University of California, Los Angeles
    Los Angeles, California, United States
    Recruiting

Study contacts

  • Principal investigator: Arpana Church, Ph.D. — The Regents of the University of California, Los Angeles
  • Study coordinator: Allison Vaughan, MPH
  • Email: ChurchLab@mednet.ucla.edu
  • Phone: 3108257206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.